Product logins

Find logins to all Clarivate products below.


The Company Franchise Analysis (CFA) provides a comprehensive evaluation of the franchise, including benchmarking, strategic insights, and an overview of marketed products. It highlights key market drivers and offers a detailed pipeline and sales analysis, along with information on deals and significant events. This profile aims to deliver a thorough understanding of the market dynamics and the strategic positioning of the franchise’s drugs.

Related Market Assessment Reports

Report
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2024
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Ovarian Cancer | Disease Landscape & Forecast | G7 | 2024
The treatment of ovarian cancer has been transformed by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (Zejula; GSK), and…
Report
Non-Small-Cell Lung Cancer | Disease Landscape & Forecast | G7 | 2024
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.), which…
Report
Urticaria | Disease Landscape & Forecast | G7 | 2024
The urticaria drug market is dominated by oral medications—including steroids and second-generation, nondrowsy antihistamines—which are prescribed for both chronic inducible urticaria (CIndU)…
Report
Systemic Lupus Erythematosus – Geographic Focus: China – China In-Depth – Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs or systems in the body. The treatment goals of physicians who manage SLE patients differ depending on…